Cargando…

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stagg, Helen R., Brown, James, Ibraim, Elmira, Riekstiņa, Vija, Viiklepp, Piret, Cīrule, Andra, Cocei, Horia, Danilovitš, Manfred, Dravniece, Gunta, Jackson, Charlotte, White, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641652/ https://www.ncbi.nlm.nih.gov/pubmed/26558611 http://dx.doi.org/10.1371/journal.pone.0142425

Ejemplares similares

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
por: Stagg, Helen R., et al.
Publicado: (2016)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
por: Mantefardo, Bahru, et al.
Publicado: (2021)

Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines
por: Feuth, T., et al.
Publicado: (2021)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia
por: Miller, Thaddeus L, et al.
Publicado: (2013)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Heightened Vulnerability to MDR-TB Epidemics after Controlling Drug-Susceptible TB
por: Bishai, Jason D., et al.
Publicado: (2010)

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
por: Singh, Pravin K., et al.
Publicado: (2019)

Clinical and socio-economic characteristics of a cohort of MDR/XDR TB patients in Bucharest, Romania
por: Ivanova, O, et al.
Publicado: (2023)

Drug Susceptibility of Mycobacterium tuberculosis Beijing Genotype and Association with MDR TB
por: de Steenwinkel, Jurriaan E.M., et al.
Publicado: (2012)

MDR TB Transmission, Singapore
por: Chee, Cynthia B.E., et al.
Publicado: (2013)

Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss
por: Modongo, Chawangwa, et al.
Publicado: (2014)

Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic
por: Kumar, G Sravan, et al.
Publicado: (2023)

Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial
por: Weng, Taoping, et al.
Publicado: (2021)

How Do Patients Who Fail First-Line TB Treatment but Who Are Not Placed on an MDR-TB Regimen Fare in South India?
por: Burugina Nagaraja, Sharath, et al.
Publicado: (2011)

"Treatment is of primary importance, and social assistance is secondary": A qualitative study on the organisation of tuberculosis (TB) care and patients' experience of starting and staying on TB treatment in Riga, Latvia
por: Kielmann, Karina, et al.
Publicado: (2018)

Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar
por: Wai, Pyae Phyo, et al.
Publicado: (2018)

Mortality among MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors
por: Chung-Delgado, Kocfa, et al.
Publicado: (2015)

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic
por: Udwadia, Zarir F., et al.
Publicado: (2019)

Management of MDR-TB: Review of Iran's Experience
por: Masjedi, Mohammad Reza, et al.
Publicado: (2013)

MDR-TB in Pakistan: Challenges, efforts, and recommendations
por: Khan, Mahad Ahmed, et al.
Publicado: (2022)

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting
por: Mitnick, Carole D, et al.
Publicado: (2015)

The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study
por: Ghimire, Samiksha, et al.
Publicado: (2020)

Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
por: Mehari, Kibriti, et al.
Publicado: (2019)

Why has MDR-TB prevalence increased in Iran?
por: Heidary, Mohsen, et al.
Publicado: (2016)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
por: Ali, Monadil H., et al.
Publicado: (2019)

Fluoroquinolone preventive therapy for children exposed to MDR-TB
por: Gureva, T., et al.
Publicado: (2022)

Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2019)

Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India
por: Kundu, Debashish, et al.
Publicado: (2018)

Collaborative public–private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012–2016
por: Shelby, Peter W, et al.
Publicado: (2017)

759. Molecular Characterization and Epidemiology of Multidrug-Resistant Mycobacterium tuberculosis (MDR-TB) and Identification of Possible Cases of Local Transmission of MDR-TB in Kuwait
por: Mokaddas, Eiman, et al.
Publicado: (2018)

Correction: The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia
por: Soeroto, Arto Yuwono, et al.
Publicado: (2022)

Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals
por: Mukonzo, Jackson, et al.
Publicado: (2019)

Correction to: Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2020)

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates
por: Kaniga, Koné, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aehl4jtujg89rc36bq60dlf620